Tissue Expression and Plasma Soluble PD-L1 Levels in Patients With Endometrial Cancer.

IF 1.6 4区医学 Q4 ONCOLOGY

Anticancer research Pub Date : 2024-12-01 DOI:10.21873/anticanres.17378

Emmanuel Kontomanolis, Antonios Koutras, Achilleas G Mitrakas, Grigorios Trypsianis, Konstantinos Nikolettos, Panagiotis Tsikouras, Nikolaos Nikolettos, Alexandra Giatromanolaki, Michael Koukourakis

{"title":"Tissue Expression and Plasma Soluble PD-L1 Levels in Patients With Endometrial Cancer.","authors":"Emmanuel Kontomanolis, Antonios Koutras, Achilleas G Mitrakas, Grigorios Trypsianis, Konstantinos Nikolettos, Panagiotis Tsikouras, Nikolaos Nikolettos, Alexandra Giatromanolaki, Michael Koukourakis","doi":"10.21873/anticanres.17378","DOIUrl":null,"url":null,"abstract":"Background/aim: The prognostic role of tissue PD-L1 expression in endometrial cancer (EC) remains controversial. Moreover, its value in guiding anti-PD1/PD-L1 immunotherapy is questionable. The eventual role of soluble PD-L1 (sPD-L1), released by cancer tissue and circulating immune cells, is largely unexplored.Patients and methods: In this pilot study, we investigated the expression of PD-L1 in cancer cells and tumor stroma infiltrating inflammatory cells (TIICs), in parallel with sPD-L1 levels in the plasma of 19 patients with early-stage endometrioid EC, before and after hysterectomy.Results: Cancer cell membrane staining was noted in 5/19 (26.3%) cases (range=1-5%; median 1% of the cancer cell population). IICs showed positive reactivity in 14/19 (73.7%) cases. sPD-L1 plasma levels ranged from 53-408 pg/ml and 113-557 pg/ml, respectively, in the plasma of patients before and after hysterectomy (p=0.01). High PD-L1 expression by IIC was marginally associated with a high histology grade (p=0.08). High sPD-L1 levels before surgery were significantly associated with ICC PD-L1 expression (p=0.0007), high histology grade (p=0.04), and marginally with T2-stage (p=0.08).Conclusion: sPD-L1 is easily detectable in the plasma of EC patients and may be associated with aggressive clinical features and PD-L1-expressing immune cells infiltrating the tumor stroma. sPD-L1 plasma levels in EC patients undergoing immunotherapy can be further tested as a biomarker for therapeutic stratification.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"44 12","pages":"5525-5530"},"PeriodicalIF":1.6000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17378","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: The prognostic role of tissue PD-L1 expression in endometrial cancer (EC) remains controversial. Moreover, its value in guiding anti-PD1/PD-L1 immunotherapy is questionable. The eventual role of soluble PD-L1 (sPD-L1), released by cancer tissue and circulating immune cells, is largely unexplored.

Patients and methods: In this pilot study, we investigated the expression of PD-L1 in cancer cells and tumor stroma infiltrating inflammatory cells (TIICs), in parallel with sPD-L1 levels in the plasma of 19 patients with early-stage endometrioid EC, before and after hysterectomy.

Results: Cancer cell membrane staining was noted in 5/19 (26.3%) cases (range=1-5%; median 1% of the cancer cell population). IICs showed positive reactivity in 14/19 (73.7%) cases. sPD-L1 plasma levels ranged from 53-408 pg/ml and 113-557 pg/ml, respectively, in the plasma of patients before and after hysterectomy (p=0.01). High PD-L1 expression by IIC was marginally associated with a high histology grade (p=0.08). High sPD-L1 levels before surgery were significantly associated with ICC PD-L1 expression (p=0.0007), high histology grade (p=0.04), and marginally with T2-stage (p=0.08).

Conclusion: sPD-L1 is easily detectable in the plasma of EC patients and may be associated with aggressive clinical features and PD-L1-expressing immune cells infiltrating the tumor stroma. sPD-L1 plasma levels in EC patients undergoing immunotherapy can be further tested as a biomarker for therapeutic stratification.

查看原文本刊更多论文

子宫内膜癌患者的组织表达和血浆可溶性PD-L1水平。

背景/目的：组织PD-L1表达在子宫内膜癌（EC）中的预后作用仍有争议。此外，其在指导抗pd1 /PD-L1免疫治疗中的价值也值得怀疑。可溶性PD-L1 （sPD-L1）由癌症组织和循环免疫细胞释放，其最终作用在很大程度上尚未被探索。患者和方法：在这项前期研究中，我们研究了19例子宫切除术前后早期子宫内膜样EC患者的癌细胞和肿瘤基质浸润性炎症细胞（TIICs）中PD-L1的表达，以及血浆中sPD-L1的水平。结果：5/19例（26.3%）患者有癌细胞膜染色(范围=1 ~ 5%；中位数占癌细胞总数的1%)。IICs阳性反应14/19（73.7%）。子宫切除术前后患者血浆sPD-L1水平分别为53 ~ 408 pg/ml和113 ~ 557 pg/ml （p=0.01）。IIC中PD-L1的高表达与高组织学分级呈正相关（p=0.08）。术前高sPD-L1水平与ICC PD-L1表达显著相关（p=0.0007），高组织学分级（p=0.04），与t2期轻微相关（p=0.08）。结论：sPD-L1易在EC患者血浆中检测到，可能与侵袭性临床特征和表达pd - l1的免疫细胞浸润肿瘤基质有关。接受免疫治疗的EC患者的血浆sPD-L1水平可以作为治疗分层的生物标志物进一步检测。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Anticancer research 医学-肿瘤学

CiteScore

3.70

自引率

10.00%

发文量

566

审稿时长

2 months

期刊介绍： ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed. ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies). Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.